A change in status for blood plasma

As a crucial element in blood transfusions, until recently plasma was considered a labile blood product, handled by the French Blood Agency (EFS). The implementation of a recent ruling from the European Court of Justice means that from 31st January 2015 onwards it is to be defined as a “medicinal product derived from blood.” As the EFS is not an accredited pharmaceutical agency, it will no longer be authorized to manufacture blood plasma.